Skip to main content
. 2021 Jan 25;13(2):351. doi: 10.3390/nu13020351

Figure 4.

Figure 4

Potential therapeutic effects of GLP-1RA administration in obese patients with co-existing cardiometabolic disorders. T2DM: type 2 diabetes mellitus; NAFLD: non-alcoholic fatty liver disease; CVD: cardiovascular disease. ↑: increase; ↓: decrease.